MLTX
Price
$15.37
Change
+$5.99 (+63.86%)
Updated
Feb 3 closing price
Capitalization
1.12B
22 days until earnings call
Intraday BUY SELL Signals
NUVL
Price
$107.17
Change
+$19.17 (+21.78%)
Updated
Feb 3 closing price
Capitalization
8.15B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MLTX vs NUVL

Header iconMLTX vs NUVL Comparison
Open Charts MLTX vs NUVLBanner chart's image
MoonLake Immunotherapeutics
Price$15.37
Change+$5.99 (+63.86%)
Volume$1.07M
Capitalization1.12B
Nuvalent
Price$107.17
Change+$19.17 (+21.78%)
Volume$357.26K
Capitalization8.15B
MLTX vs NUVL Comparison Chart in %
MLTX
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MLTX vs. NUVL commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLTX is a Hold and NUVL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (MLTX: $15.79 vs. NUVL: $104.95)
Brand notoriety: MLTX and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLTX: 61% vs. NUVL: 92%
Market capitalization -- MLTX: $1.12B vs. NUVL: $8.15B
MLTX [@Biotechnology] is valued at $1.12B. NUVL’s [@Biotechnology] market capitalization is $8.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $119.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLTX’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • MLTX’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than MLTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLTX’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 6 bullish TA indicator(s).

  • MLTX’s TA Score: 4 bullish, 6 bearish.
  • NUVL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than MLTX.

Price Growth

MLTX (@Biotechnology) experienced а -0.75% price change this week, while NUVL (@Biotechnology) price change was -1.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.27%. For the same industry, the average monthly price growth was +3.31%, and the average quarterly price growth was +36.66%.

Reported Earning Dates

MLTX is expected to report earnings on Feb 26, 2026.

NUVL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($8.15B) has a higher market cap than MLTX($1.12B). MLTX YTD gains are higher at: 19.803 vs. NUVL (4.334). MLTX has higher annual earnings (EBITDA): -227.94M vs. NUVL (-398.38M). NUVL has more cash in the bank: 943M vs. MLTX (380M). MLTX (0) and NUVL (0) have equivalent revenues.
MLTXNUVLMLTX / NUVL
Capitalization1.12B8.15B14%
EBITDA-227.94M-398.38M57%
Gain YTD19.8034.334457%
P/E RatioN/AN/A-
Revenue00-
Total Cash380M943M40%
Total Debt75.7MN/A-
TECHNICAL ANALYSIS
Technical Analysis
MLTXNUVL
RSI
ODDS (%)
Bearish Trend 2 days ago
61%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 9 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
MLTX
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CVMRX25.030.14
+0.56%
Calvert Emerging Markets Equity R6
LFGAX40.790.13
+0.32%
Lord Abbett Focused Growth A
HQIVX21.360.04
+0.19%
Hartford Equity Income R6
ISCWX104.410.03
+0.03%
Voya Multi-Manager International Sm Cp W
NZDCHF0.47N/A
N/A
New Zealand Dollar - Switzerland Franc

MLTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLTX has been closely correlated with KALA. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLTX jumps, then KALA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLTX
1D Price
Change %
MLTX100%
+0.77%
KALA - MLTX
84%
Closely correlated
-0.47%
NEVPF - MLTX
70%
Closely correlated
N/A
IOBT - MLTX
60%
Loosely correlated
-4.17%
XNCR - MLTX
50%
Loosely correlated
+0.17%
NUVL - MLTX
48%
Loosely correlated
+2.00%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XNCR. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.00%
XNCR - NUVL
61%
Loosely correlated
+0.17%
RVMD - NUVL
59%
Loosely correlated
+0.22%
IDYA - NUVL
59%
Loosely correlated
+5.81%
XENE - NUVL
58%
Loosely correlated
+1.07%
CLDX - NUVL
55%
Loosely correlated
+0.24%
More